Pemitinib Tablets — Pemigatinib 13.5 mg (14 Tabs) Everest

Prescribed by oncologists for adults with:

• 🔹 Cholangiocarcinoma (Bile Duct Cancer): Previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a confirmed FGFR2 fusion or other rearrangement.
• 🔹 Myeloid/Lymphoid Neoplasms: With FGFR1 rearrangement (relapsed or refractory).

Sales Unit: Bottle containing 14 film-coated tablets (13.5 mg strength).

⚠️ APPLICATION INSTRUCTIONS:

• Standard Dosage: Take one tablet (13.5 mg) orally once daily at approximately the same time every day.
• Cycle Schedule: Take for 14 consecutive days followed by a 7-day break (21-day cycle). Continue as long as beneficial.
• Administration: Swallow whole with or without food. Do not crush, chew, or split the tablet.
• ✋ Missed Dose: If missed by more than 4 hours, skip it. Resume regular schedule the next day. Do not take 2 tablets to make up for the missed dose.

• ⛔ Pregnancy & Breastfeeding: Can cause fetal harm. Effective contraception is required during treatment and for 1 week after the last dose.
• Pediatric patients (safety not established).
• Hypersensitivity to Pemitinib or any excipients.
• Co-administration with strong CYP3A inducers (e.g., St. John's wort) should be avoided.

• ⛔ Pregnancy & Breastfeeding: Can cause fetal harm. Effective contraception is required during treatment and for 1 week after the last dose.
• Pediatric patients (safety not established).
• Hypersensitivity to Pemitinib or any excipients.
• Co-administration with strong CYP3A inducers (e.g., St. John's wort) should be avoided.